Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Hits Pause On M&A To See How US Tax Reform Plays

Executive Summary

CEO Ian Read indicated the company will wait to see if the US tax system is overhauled before completing any large-scale M&A, even as many investors are anxious to see Pfizer make an acquisition.

Advertisement

Related Content

Deal Watch: Takeda Continues Transaction Spree With Four More Deals
Is BMS The Must Have Immuno-Oncology Accessory Of The Season?
Pfizer's Xeljanz: The Slow Road To Blockbuster Status
Xtandi Sales Disappoint Pfizer, Returning Focus To The High-Priced Deal
Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer
Pharma Is Ready And Waiting For A Tax Holiday Under Trump
It's The End Of Pfizergan, So Pfizer Will Have To Grow It Alone

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel